Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Causes

    ... De Novo MDS The cause of most MDS cases is ... call this: Therapy-related MDS Secondary MDS On average, treatment-related MDS happens 5 to 7 years ...

    Topic section last updated 03/10/2016 - 10:59pm.

  2. Youmna Kfoury, PhD

    ... Myelodysplastic Syndromes (MDS) are a group of diverse and incurable pre-leukemic disorders. Even though a ... Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852-857. Sacchetti, B., Funari, A., ...

    Grant Recipient last updated 12/15/2016 - 12:56pm.

  3. David Araten, MD

    ... Secondary mutations and thrombosis in PNH ... with the generous support of the Aplastic Anemia and MDS International Foundation, to test a larger number of patients for mutations ...

    Grant Recipient last updated 11/30/2016 - 10:51am.

  4. Hematopoietic Stem Cell Transplantation in Aplastic Anemia

    ... risk of developing myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).  Many patients treated with ... Also, remember that if aplastic anemia develops into MDS or AML, then outcomes aren’t as good. The survival is lower due to ... What is not known is if eltrombopag affects the risk of secondary events such as relapse and clonal progression, especially in the ...

    Interview last updated 11/28/2016 - 2:58pm.

  5. Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... AML arising from MDS or a myeloproliferative disorder, or secondary AML Presence of Flt3 internal tandem duplications Poor-risk ...

    Clinical Trial last updated 05/02/2016 - 2:38pm.

  6. Legal and Privacy Notices

    ... General Disclaimer The Aplastic Anemia and MDS International Foundation (AAMDSIF) created and maintains this Web site as a ... offered by the AAMDSIF. Users may opt out of any such secondary use of personal information by calling the AAMDSIF at (800) 747-2820. ...

    Page last updated 11/01/2016 - 11:24am.

  7. Bone Marrow Transplant

    ... doctor about bone marrow transplant options. MDS : Whether patients with MDS should undergo hematopoietic stem cell transplantation (HSCT) as soon as ... can also affect SCT outcomes. People with secondary MDS , caused by a previous treatment for another disease or ...

    Topic section last updated 03/29/2016 - 7:27pm.

  8. Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

    ... to patients with relapsed and/or refractory AML, MDS, or ALL. Status:  ... PHASE I -- a. Primary or secondary AML according to WHO classification, with relapsed or refractory ...

    Clinical Trial last updated 06/06/2016 - 10:59am.

  9. Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... CD123+ acute myeloid leukemia (AML) de novo , or secondary Relapsed AML is defined as patients that had a first ...

    Clinical Trial last updated 07/14/2016 - 4:08pm.

  10. Myelofibrosis (MF)

    ... vera or essential thrombocytosis. This is called secondary myelofibrosis. Patients with MDS, leukemia or even lymphoma can also have fibrosis in their bone ...

    Topic section last updated 07/07/2016 - 3:16pm.